You are here

Harry Evans

Harry Evans


Harry is a senior IP and TMT specialist based in Singapore.



Harry is a technology, media and telecommunications (TMT) lawyer advising clients on business-critical information technology, intellectual property (IP) and general commercial issues. 
He has extensive experience in advising major financial, pharmaceutical and consumer goods companies on the IT and intellectual aspects of corporate transactions. Harry has worked on a wide range of complex high-value commercial agreements, including outsourcing, IP licensing, development and commercialisation, and software development.
Harry's experience includes advising:
  • a global bank on procuring the IT infrastructure necessary for its new digital bank in Hong Kong. The matter involved negotiating over 11 separate IT supply agreements, for the infrastructure, platform and software necessary for the new digital bank, with some of the biggest and most advanced global tech companies
  • a global bank on the design and development of approximately thirty-five (35) template agreements, as part of a third party risk management program, including agreements covering business process outsourcings, IT outsourcings, cloud service arrangements (including hosting and SaaS services) and platform, hardware, software and services supply arrangements
  • a major SE Asia ride-hailing and Super-App company on the preparation and negotiation of a long-term, high value collaboration agreement with a bank regarding the provision of financial services through the company’s platform
  • Europe’s leading payments processing company in relation to various commercial arrangements for the provision of payments processing services to merchants globally, including BIN Sponsorship Agreements, Merchant Agreements, Payment Facilitator Agreements
  • Lupin, an Indian based pharmaceutical company on the US$526 million divestment of Kyowa Pharmaceuticals Industry to Unison Capital Partners
  • Strides Pharma, an Indian based pharmaceutical company, on the preparation and negotiation of a long-term, high value exclusive product supply agreement, relating to the divestment of various Australian assets
  • Novartis on the IP issues associated with the sale of its vaccines business to GSK for US$7bn, the purchase of GSK’s oncology business for US$16bn, and the sale of Novartis’ flu business to CSL for $275 million. Resolved myriad IP issues over 3-year (and ongoing) period




Harry has over 10 years’ experience advising clients on business-critical information technology (IT), intellectual property (IP) and general commercial issues. He has a particular interest in the technology, financial services, pharmaceutical, life sciences and consumer sectors, and has advised clients on a wide range of complex, high-value commercial arrangements. Harry also has extensive experience advising clients on the IP/IT aspects of corporate transactions, and on strategies for commercialising technology/IP and managing IP disputes. Before moving to Singapore, Harry worked in both London and Melbourne. Harry is a qualified lawyer in England & Wales and Australia (Victoria), and a registered foreign lawyer in Singapore.

Harry graduated with degrees in law (hons) and science (genetics major) from the University of Melbourne.

Related content

13th January 2022
A new wave of potent digital tools promise to super-charge finance houses’ climate efforts. But...

Related news and deals

28 April 2022

Herbert Smith Freehills continues expansion in Asia with partner and counsel promotions